NASDAQ$BLFS

BioLife Solutions Inc · Q1 2024 earnings

Q1 2024 earnings · · Investor relations

Briefing

Reported solid start to 2024 with sequential core cell processing revenue platform growth, strategic realignment to concentrate on most valuable franchises and the divestiture of the Global Cooling, Inc. (“GCI”) freezer business.

BioLife Solutions reported a decrease in total revenue for Q1 2024, but saw sequential growth in its core cell processing platform. The company divested its GCI freezer business in April, which is expected to improve its financial profile. The company affirmed its revenue guidance for 2024.

  • Cell Processing revenue increased 10% sequentially to $16.2 million
  • GAAP gross margin of 38% and net loss of $10.2 million
  • Non-GAAP adjusted gross margin expands from 40% to 53% and adjusted EBITDA of $3.6 million or 13% ex-GCI freezers
  • Processed 22 new U.S. FDA Master File cross references for our biopreservation media, bringing the cumulative total processed to 716.

Headline financials

Total Revenue

$31.7M

Previous: $37.7M-15.9%
EPS

-$0.22

Previous: -$0.27+18.5%
GAAP gross margin

63.0%

Previous: 35.0%+80.0%
Non-GAAP adjusted gross margin

66.0%

Previous: 37.0%+78.4%
GAAP operating loss

-$3.3M

Previous: -$13.6M+75.8%
Adjusted EBITDA

$2.6M

Previous: -$1.9M+236.8%
Free Cash Flow

-$10.2M

Previous: -$17M+39.9%
Net Income

-$10.2M

Previous: -$13.7M+25.5%
Operating Income

-$10.1M

Previous: -$13.6M+25.6%
Cash & Equivalents

$29.7M

Previous: $19.1M+55.4%
Total Assets

$402M

Previous: $446M-10.0%
R&D Expense

$3.53M

No prior period
Stock-Based Comp

$6.18M

Previous: $7.36M-16.0%

Revenue & EPS history

BioLife · Revenue · Quarterly

$31.7M

Q1 2024-15.9%vs Q1 2023
Beat estimate in 11 of 14 quarters(79%)
ActualEstimate

Revenue by segment

BioLife · $22.7M total across 2 segments · Q4 2024

  • Cell Processing platform
    $20.3M
  • evo and Thaw platform
    $2.4M

Forward guidance

BioLife Solutions is affirming its 2024 revenue guidance of $95.5 million to $100.0 million. This is based on expectations for BioLife's Cell Processing and Biostorage Services platforms, which now include results from its ThawSTAR product line and do not include revenue from the freezer product line (GCI and CBS). Management expects full year positive adjusted EBITDA and adjusted EBITDA growth in 2024.

Tailwinds

  • Cell Processing platform: $66.0 million to $68.5 million, an increase of 0% to 4% compared with 2023.
  • Compared with annualizing the second half of 2023 revenue run rate, the growth would be 17% to 22%
  • Biostorage Services platform: $29.5 million to $31.5 million, an increase of 5% to 12% compared with 2023.
  • This platform now includes the ThawSTAR automated thawing product line.
  • Without ThawSTAR, the growth rate would be 10% to 16%.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2024

Historical avgQ1 2024

+0.1%

Avg return

Earnings day

+0.8%

Avg return

5 days after

+4.3%

Avg return

30 days after

44%

22 / 50 earnings

Positive

+21.4%

Q3 2022

Best reaction

-34.5%

Q4 2019

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+6.3%-2.4%+22.4%
Q4 2025+8.0%-8.1%-17.3%
Q3 2025-4.2%-4.1%-5.8%
Q2 2025+10.0%+24.4%+28.2%
Q1 2025+4.0%-1.4%+6.0%
Q4 2024+2.1%+7.6%-0.9%
Q3 2024-9.4%-21.0%+0.5%
Q2 2024+14.5%+20.3%+7.9%
Q1 2024+8.9%+25.0%+13.2%
Q4 2023+5.1%-0.5%+8.5%
Q3 2023-5.7%+3.1%+14.2%
Q2 2023-29.7%-34.9%-30.3%
Q1 2023-2.9%+3.5%+20.6%
Q4 2022+0.2%+2.7%-7.4%
Q3 2022+21.4%+14.1%-4.6%
Q2 2022+13.7%+15.7%+25.6%
Q1 2022-3.8%+1.6%+18.3%
Q4 2021-0.3%+0.9%-3.7%
Q3 2021-6.0%+5.2%-30.3%
Q2 2021-1.8%-3.9%+12.0%
Q1 2021-2.1%+4.8%+25.1%
Q4 2020+8.3%-7.8%-14.7%
Q3 2020+5.8%+0.8%+21.6%
Q2 2020+0.3%-5.4%+5.6%
Q1 2020+3.0%+10.5%+1.5%
Q4 2019-34.5%-36.7%-27.8%
Q3 2019-12.8%-8.8%-7.4%
Q2 2019-6.2%+1.1%+7.7%
Q1 2019-2.4%+4.5%+8.8%
Q4 2018+10.7%+19.4%+5.5%
Q3 2018+15.0%-8.0%-7.8%
Q2 2018-4.8%-1.0%+2.3%
Q1 2018-3.7%+7.6%+23.5%
Q4 2017-4.4%-10.2%+22.4%
Q3 2017+18.0%+21.6%+8.2%
Q2 2017+3.8%+8.2%+30.6%
Q1 2017+3.7%-1.4%+7.8%
Q4 2016-5.0%-9.5%-7.7%
Q3 2016+0.7%+2.7%+5.4%
Q2 2016-2.4%-7.7%-15.9%
Q3 2012+10.0%
Q1 2012+0.0%
Q4 2011+0.0%
Q3 2011+0.0%
Q2 2011-14.3%
Q1 2011+0.0%
Q4 2010-11.1%
Q3 2010+0.0%
Q2 2010+0.0%
Q1 2010+0.0%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro